Concepta inks global licence agreement with Abingdon Health
The UK-personalised healthcare company said the deal will allow its customers to access rapid test results, further information and remain connected with supporting services at home.
A smartphone software, App Dx uses an in-built camera functionality to read single or multiple test lines to give test results and provides ‘lab-quality data’ for immediate viewing in a clinic.
Tests can be performed rapidly in any location, the group outlined, and allows any patient and/or healthcare professional access to advice and easy connectivity to a healthcare team.
Shares in Concepta were trading flat at 1.65p on Monday morning.
Concepta and Abingdon Health will commence development work in May 2020.
The partnership follows a recent outsourcing agreement with Abingdon for Concepta’s home-use fertility tracking and pregnancy testing system, myLotus®.
The group said App Dx represents a platform that responds to evolving market needs as consumer connectivity in the femtech space ‘continues to build momentum.’
According to consulting firm Frost & Sullivan, the femtech market revenue is expected to reach $1.1 billion by 2024, growing at a compound annual growth rate (CAGR) of 12.9%.
Penny McCormick, Chief Executive of Concepta said the licence will help the group’s patients with testing “in an even more convenient way that is complementary to our portfolio.”
“Abingdon's leading-edge App Dx technology is perfectly suited to enhance Concepta's digital health strategy and support this highly engaged user group through their fertility journeys,” adde Chris Yates, Chief Executive of Abingdon Health.
Follow News & Updates from Concepta here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.